Q&A: hVivo’s Mo Khan on the company’s latest mega-deal
Episode 1742, Dec 13, 2023, 07:45 AM
(Watch the video interview HERE)
Mo Khan, chief executive of hVivo #HVO, tells Vox about a new £17m human challenge contract with an existing customer, and the progress the company’s made to deliver better than expected results this year.
0:41 Mo Khan explains the details of the latest human challenge contract, a £17m deal with an existing top 5 global pharma group to test its respiratory syncytial virus (“RSV”) antiviral drug candidate, to be delivered over 2024 and 2025.
2:35 How this multi multi-cohort trial differs from the more common drug-versus-placebo approach, allowing customers to assess dosing as well as efficacy by more closely mirroring real world disease progress and further derisk
5:32 A flavour of this year’s numbers and how operational efficiencies have driven Ebitda margins over 20%, of which further details will be provided in a fuller trading update in January.
Mo Khan, chief executive of hVivo #HVO, tells Vox about a new £17m human challenge contract with an existing customer, and the progress the company’s made to deliver better than expected results this year.
0:41 Mo Khan explains the details of the latest human challenge contract, a £17m deal with an existing top 5 global pharma group to test its respiratory syncytial virus (“RSV”) antiviral drug candidate, to be delivered over 2024 and 2025.
2:35 How this multi multi-cohort trial differs from the more common drug-versus-placebo approach, allowing customers to assess dosing as well as efficacy by more closely mirroring real world disease progress and further derisk
5:32 A flavour of this year’s numbers and how operational efficiencies have driven Ebitda margins over 20%, of which further details will be provided in a fuller trading update in January.